Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acasti Pharma (TSV: ACST )

0.5800 UNCHANGED
Last Price Updated: 11:24 AM EDT, Mar 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.5800
Bid (Size) 0.5800 (30)
Ask (Size) 0.9800 (5)
Prev. Close 0.5800
Today's Range 0.5800 - 0.5800
52wk Range 0.4700 - 1.340
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Acasti Pharma Reports Third Quarter 2023 Operational Results
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule
From Acasti Pharma, Inc.
Via GlobeNewswire

Performance

YTD
-15.94%
-15.94%
1 Month
N/A
N/A
3 Month
-10.77%
-10.77%
6 Month
+11.54%
+11.54%
1 Year
-50.85%
-50.85%

More News

Read More
Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Pharma Reports Second Quarter 2023 Operational Results
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Pharma to Present at Q4 Investor Summit
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Announces Court Dismissal of Stockholder Litigation
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th
From Acasti Pharma Inc.
Via AccessWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.